LQVTDSGLYRCVIYHPP TFA

• CAT Number: I042802
• Molecular Formula: C91H138F3N23O27S
• Molecular Weight: 2075.27
• Purity: ≥95%

LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1[1].
LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model[1].
LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK[1].
LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice[1].

Reference

[1]. Pengfei Xu, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis. 2019 Jul 19;10(8):555.
 [Content Brief]